Summit Therapeutics plc (SMMT) News

Summit Therapeutics plc (SMMT)

Today's Latest Price: $3.27 USD

0.05 (-1.51%)

Updated Oct 30 4:00pm

Add SMMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter SMMT News Items

SMMT News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest SMMT News From Around the Web

Below are the latest news stories about Summit Therapeutics Inc that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Summit Therapeutics +3.8% as Zanganeh reports 7.8% stake

Summit Therapeutics (SMMT) is up 3.8% after-hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares, and...

Seeking Alpha | September 28, 2020

Summit Therapeutics +3.8% as Zanganeh reports 7.8?% stake

Summit Therapeutics (SMMT) is up 3.8% after hours after an SEC filing shows a 7.8% stake taken by Maky Zanganeh. That comes via Zanganeh, her revocable trust, and the irrevocable trust of Shaun Zanganeh. The aggregate amount of shares beneficially owned amounts to 5.330,258. (Each trust holds about 2.104M shares,...

Seeking Alpha | September 28, 2020

Summit Announces Intention to Redomicile its Holding Company to the United States

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA,.

Yahoo | July 16, 2020

Summit Therapeutics announces publication of ridinilazole data

Thinly traded micro cap Summit Therapeutics ([[SMMT]] +0.5%) is in the green, albeit trailing the broad market and on turnover of only 9.3K shares, on the heels of the publication of data from a Phase 2 clinical trial, CoDIFy, (that ended in October 2015) comparing small molecule antibiotic ridinilazole to vancomycin...

Seeking Alpha | July 13, 2020

Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,.

Yahoo | July 13, 2020

Summit appoints Michael Donaldson as CFO

Summit Therapeutics (SMMT) has appointed Mr. Michael Donaldson as Chief Financial Officer, effective immediately. Mr. Donaldson joins Summit from Goldfinch Bio, Inc., where he served as Vice President, Finance, and Corporate Controller....

Seeking Alpha | June 8, 2020

Summit Appoints Michael Donaldson as Chief Financial Officer

Summit Therapeutics plc (SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance. “Michael joins us at an exciting time in Summit’s growth with our ongoing Phase 3 clinical trials of our precision antibiotic candidate, ridinilazole, and the potential to bring a superior product to patients with C. difficile infection,” said Mr. Bob Duggan, Executive Chairman and Chief Executive Officer of Summit.

Yahoo | June 8, 2020

Is Summit Therapeutics PLC (SMMT) A Good Stock To Buy?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 5, 2020

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months.

Yahoo | June 2, 2020

Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

Is (SMMT) Outperforming Other Medical Stocks This Year?

Yahoo | June 1, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5867 seconds.